A tougher stance in the UK on funding expensive medicines for rare diseases is raising questions about the government’s pledges to support a life-sciences industry that is already rattled by Brexit.
A proposal to introduce a cap on coverage of treatments within the state-run health system would have a significant impact on access to ultra-rare disease drugs, Alexion Pharmaceuticals Inc senior vice president of global government affairs Heidi Wagner said.
Last week, the US biotech company was denied support in England for Kanuma, a drug that is estimated to cost ￡492,000 (US$612,000) a year, because a key authority deemed it too expensive even after unspecified discounts.
“Perhaps England is not going to be as supportive of innovation as it was in the past,” she said. There are a number of signals “that would really call that into question.”
Adding a funding threshold for new therapies that tackle very rare diseases, part of broader measures to keep a lid on costs, could make it harder for makers of those drugs to recoup the costs of developing treatments used by few patients globally.
UK Prime Minister Theresa May’s government last month detailed plans to encourage innovation as she sought to alleviate concerns that the UK’s exit from the EU might curtail investment in science and technology and erode the nation’s attractiveness for global talent.
The British National Health Service (NHS) has said it is committed to providing timely access to new drugs and must balance helping companies with ensuring its financial sustainability.
With Alexion’s Kanuma, costs were too high even with the offered discount, said the UK National Institute for Health and Care Excellence, which advises the NHS on coverage of new drugs.
The drug treats a rare and deadly disease called lysosomal acid lipase deficiency, which mostly afflicts children. Babies diagnosed with an aggressive form of the disease have a median life expectancy of 3.7 months.
Alexion is still seeking to reach an agreement with the health system after the “sizable” discount it proposed was rejected, Wagner said.
Last week, it said that UK health authorities were disregarding expert medical opinion.
Earlier this month, the firm suffered another blow from a separate UK judgement that is likely to restrict access of its drug Strensiq to some patients.
KEEPING UP: The acquisition of a cleanroom in Taiwan would enable Micron to increase production in a market where demand continues to outpace supply, a Micron official said Micron Technology Inc has signed a letter of intent to buy a fabrication site in Taiwan from Powerchip Semiconductor Manufacturing Corp (力積電) for US$1.8 billion to expand its production of memory chips. Micron would take control of the P5 site in Miaoli County’s Tongluo Township (銅鑼) and plans to ramp up DRAM production in phases after the transaction closes in the second quarter, the company said in a statement on Saturday. The acquisition includes an existing 12 inch fab cleanroom of 27,871m2 and would further position Micron to address growing global demand for memory solutions, the company said. Micron expects the transaction to
Vincent Wei led fellow Singaporean farmers around an empty Malaysian plot, laying out plans for a greenhouse and rows of leafy vegetables. What he pitched was not just space for crops, but a lifeline for growers struggling to make ends meet in a city-state with high prices and little vacant land. The future agriculture hub is part of a joint special economic zone launched last year by the two neighbors, expected to cost US$123 million and produce 10,000 tonnes of fresh produce annually. It is attracting Singaporean farmers with promises of cheaper land, labor and energy just over the border.
US actor Matthew McConaughey has filed recordings of his image and voice with US patent authorities to protect them from unauthorized usage by artificial intelligence (AI) platforms, a representative said earlier this week. Several video clips and audio recordings were registered by the commercial arm of the Just Keep Livin’ Foundation, a non-profit created by the Oscar-winning actor and his wife, Camila, according to the US Patent and Trademark Office database. Many artists are increasingly concerned about the uncontrolled use of their image via generative AI since the rollout of ChatGPT and other AI-powered tools. Several US states have adopted
A proposed billionaires’ tax in California has ignited a political uproar in Silicon Valley, with tech titans threatening to leave the state while California Governor Gavin Newsom of the Democratic Party maneuvers to defeat a levy that he fears would lead to an exodus of wealth. A technology mecca, California has more billionaires than any other US state — a few hundred, by some estimates. About half its personal income tax revenue, a financial backbone in the nearly US$350 billion budget, comes from the top 1 percent of earners. A large healthcare union is attempting to place a proposal before
RSS